» Articles » PMID: 36921247

Novel Postoperative Serum Biomarkers in Atypical Meningiomas: A Multicenter Study

Overview
Journal Neurosurgery
Specialty Neurosurgery
Date 2023 Mar 15
PMID 36921247
Authors
Affiliations
Soon will be listed here.
Abstract

Background: There has been no known serum biomarker to predict the prognosis of atypical meningioma.

Objective: To investigate the prognostic impact of serum biomarkers in patients newly diagnosed with resected intracranial atypical meningiomas.

Methods: This study enrolled 523 patients with atypical meningioma who underwent surgical resection between 1998 and 2018 from 5 Asian institutions. Serum laboratory data within 1 week after surgery were obtained for analysis. Optimal cutoffs were calculated for each serum marker using the maxstat package of R.

Results: Of 523 patients, 19.5% underwent subtotal resection and 29.8% were treated with adjuvant radiation therapy (ART). Among the 523 patients, 454 were included in the multivariate analysis for the progression/recurrence (P/R) rate excluding patients with incomplete histopathologic or laboratory data. On multivariate analysis, tumor size >5 cm, subtotal resection, and postoperative aspartate aminotransferase/alanine transaminase (De Ritis) ratio >2 were associated with higher P/R rates, whereas ART and postoperative platelet count >137 × 10 3 /μL were associated with lower P/R rates. In the subgroup of patients treated with ART, tumor size >5 cm and postoperative neutrophil-to-lymphocyte ratio >21 were associated with higher P/R rates. By contrast, postoperative De Ritis ratio >2 remained an adverse prognosticator in patients not treated with ART.

Conclusion: Postoperative De Ritis ratio, platelet count, and neutrophil-to-lymphocyte ratio were revealed as a novel serum prognosticator in newly diagnosed atypical meningiomas. Additional studies are warranted to validate its clinical significance and biological background.

Citing Articles

Biomarkers for prognosis of meningioma patients: A systematic review and meta-analysis.

Aung T, Ngamjarus C, Proungvitaya T, Saengboonmee C, Proungvitaya S PLoS One. 2024; 19(5):e0303337.

PMID: 38758750 PMC: 11101050. DOI: 10.1371/journal.pone.0303337.


De Ritis ratio in elderly glioblastoma patients treated with chemoradiation: A comprehensive analysis of serum biomarkers.

Kim J, Lee H, Kim I, Lee J, Cho J, Wee C Neurooncol Adv. 2024; 6(1):vdad173.

PMID: 38288092 PMC: 10824161. DOI: 10.1093/noajnl/vdad173.


Novel Postoperative Serum Biomarkers in Atypical Meningiomas: A Multicenter Study.

Chang W, Byun H, Lee J, Park C, Kim I, Kim C Neurosurgery. 2023; 93(3):599-610.

PMID: 36921247 PMC: 10827320. DOI: 10.1227/neu.0000000000002457.

References
1.
Adeberg S, Hartmann C, Welzel T, Rieken S, Habermehl D, von Deimling A . Long-term outcome after radiotherapy in patients with atypical and malignant meningiomas--clinical results in 85 patients treated in a single institution leading to optimized guidelines for early radiation therapy. Int J Radiat Oncol Biol Phys. 2011; 83(3):859-64. DOI: 10.1016/j.ijrobp.2011.08.010. View

2.
Simpson D . The recurrence of intracranial meningiomas after surgical treatment. J Neurol Neurosurg Psychiatry. 1957; 20(1):22-39. PMC: 497230. DOI: 10.1136/jnnp.20.1.22. View

3.
Hardesty D, Wolf A, Brachman D, McBride H, Youssef E, Nakaji P . The impact of adjuvant stereotactic radiosurgery on atypical meningioma recurrence following aggressive microsurgical resection. J Neurosurg. 2013; 119(2):475-81. DOI: 10.3171/2012.12.JNS12414. View

4.
Li Y, Zhong X, Cheng G, Zhao C, Zhang L, Hong Y . Hs-CRP and all-cause, cardiovascular, and cancer mortality risk: A meta-analysis. Atherosclerosis. 2017; 259:75-82. DOI: 10.1016/j.atherosclerosis.2017.02.003. View

5.
Maggio I, Franceschi E, Di Nunno V, Gatto L, Tosoni A, Angelini D . Discovering the Molecular Landscape of Meningioma: The Struggle to Find New Therapeutic Targets. Diagnostics (Basel). 2021; 11(10). PMC: 8534341. DOI: 10.3390/diagnostics11101852. View